Future Farm (CSE:FFT) has announced the creation of a cannabis advisory board, selecting John Sweeney as its chief operating officer.
As quoted in the press release:

The Company is also pleased to announce that it has selected Mr. Chris Lesh as the Cannabis Advisory Board’s first member. Mr. Lesh has over 10 years experience within the cannabis cultivation and dispensary industry in Washington State. Mr. Lesh previously served as Production Director for Privateer Holdings, Inc. (“Privateer”) and played an important role in its success. While working for Privateer, Mr. Lesh worked with Mr. Sweeney and was responsible for the operational oversight of cannabis production at Tilray’s Vancouver facility.Tilray, which is owned by Privateer, is a global leader in medical cannabis research and production dedicated to advancing the science and safety of cannabinoid medicine for patients with a diverse range of conditions including epilepsy, cancer, chronic pain and multiple sclerosis. Tilray operates one of the largest and most sophisticated medicinal cannabis research and production facilities in the world and offers pharmaceutical grade medical cannabis products to patients, pharmacies and researchers in Australia, Canada, the European Union and the Americas.
In addition to overseeing cannabis production at Tilray, Mr. Lesh was also responsible for the sourcing of additional production capacity throughout the west coast and Canada. His knowledge, background, and expertise make Mr. Lesh a strategic addition to Future Farm’s Cannabis Advisory Board, as he will be able to add value on several different initiatives. Mr. Lesh adds great experience when it comes to sourcing capital, increasing production capacity, and setting up the facilities to operate efficiently and effectively.
“We are pleased to welcome Chris Lesh to our newly created Cannabis Advisory Board and look forward to working with him,” says Mr. William Gildea, Future Farm Technologies Inc.’s CEO and Chairman. “As we prepare to build out or cultivation business, having Chris on our Board will allow us to gain a deeper understanding of the Cannabis business the state of the market and industry trends.”


Click here to read the full press release.

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less